Skip to main content

ALS

7
Pipeline Programs
15
Companies
20
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
2
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 17 programs with unclassified modality

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Tanabe Pharma America
Tanabe Pharma AmericaNJ - Jersey City
3 programs
3
MT-1186Phase 31 trial
MT-1186Phase 31 trial
MT-1186Phase 31 trial
Active Trials
NCT04165824Completed185Est. Oct 2021
NCT04569084Terminated384Est. Sep 2023
NCT05151471Terminated202Est. Sep 2023
Kite Pharma
Kite PharmaCA - El Segundo
1 program
1
Ranolazine 500 MGPhase 21 trial
Active Trials
NCT03472950Completed14Est. Dec 2022
WaVe Life Sciences
WaVe Life SciencesJapan - Kagoshima
2 programs
2
WVE-004Phase 1/21 trial
WVE-004Phase 1/21 trial
Active Trials
NCT04931862Terminated35Est. Jun 2023
NCT05683860Terminated8Est. Jun 2023
ITB Med
ITB MedNY - New York
1 program
1
TCD601Phase 11 trial
Active Trials
NCT06453668Recruiting48Est. Nov 2029
Biogen
BiogenCAMBRIDGE, MA
2 programs
Genomic Translation for Amyotrophic Lateral Sclerosis CareN/A1 trial
[11C]-PBR28PHASE_11 trial
Active Trials
NCT02795897Completed254Est. Jun 2022
NCT04490096Terminated2Est. Mar 2022
Providence Therapeutics
1 program
ALS/MND Natural History Study Data RepositoryN/A1 trial
Active Trials
NCT05966038Recruiting5,000Est. Dec 2030
Temple Therapeutics
Temple TherapeuticsNetherlands - Geleen
1 program
ALS/MND Natural History Study Data RepositoryN/A
Clene
CleneSALT LAKE CITY, UT
1 program
CNM-Au8N/A1 trial
Active Trials
NCT06408727Temporarily Not Available
MediciNova
MediciNovaLA JOLLA, CA
1 program
MN-166N/A1 trial
Active Trials
NCT06743776Available
Biosensics
BiosensicsMA - Newton
1 program
PAMSys Activity Monitoring SystemN/A1 trial
Active Trials
NCT05271435Active Not Recruiting20Est. Jun 2026
Calico
CalicoLONG BEACH, CA
1 program
FosigotifatorPHASE_11 trial
Active Trials
NCT04948645Terminated31Est. Jul 2025
Ultragenyx Pharmaceutical
1 program
TriheptanoinPHASE_1_21 trial
Active Trials
NCT03506425Completed15Est. Mar 2019
Teva
TevaIsrael - Petach Tikva
1 program
TalampanelPHASE_24 trials
Active Trials
NCT00964730Completed135Est. Feb 2010
NCT00696332Completed559Est. May 2010
NCT00036296Completed22Est. Feb 2007
+1 more trials
Genentech
GenentechCA - Oceanside
1 program
TocilizumabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT02469896Completed22Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Tanabe Pharma AmericaMT-1186
Tanabe Pharma AmericaMT-1186
Tanabe Pharma AmericaMT-1186
Kite PharmaRanolazine 500 MG
GenentechTocilizumab
TevaTalampanel
TevaTalampanel
WaVe Life SciencesWVE-004
WaVe Life SciencesWVE-004
Ultragenyx PharmaceuticalTriheptanoin
TevaTalampanel
ITB MedTCD601
CalicoFosigotifator
Biogen[11C]-PBR28
TevaTalampanel

Showing 15 of 18 trials with date data

Clinical Trials (20)

Total enrollment: 7,126 patients across 20 trials

NCT05151471Tanabe Pharma AmericaMT-1186

Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS

Start: Jan 2022Est. completion: Sep 2023202 patients
Phase 3Terminated
NCT04569084Tanabe Pharma AmericaMT-1186

Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS

Start: Nov 2020Est. completion: Sep 2023384 patients
Phase 3Terminated
NCT04165824Tanabe Pharma AmericaMT-1186

Safety Study of Oral Edaravone Administered in Subjects With ALS

Start: Nov 2019Est. completion: Oct 2021185 patients
Phase 3Completed
NCT03472950Kite PharmaRanolazine 500 MG

Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis

Start: Jun 2018Est. completion: Dec 202214 patients
Phase 2Completed
NCT02469896GenentechTocilizumab

A Trial of Tocilizumab in ALS Subjects

Start: Nov 2015Est. completion: Jul 201822 patients
Phase 2Completed
NCT00696332TevaTalampanel

Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Start: Sep 2008Est. completion: May 2010559 patients
Phase 2Completed
NCT00034814TevaTalampanel

Multicenter Trial for Adults With Partial Seizures

Start: Jan 2002Est. completion: Jan 2006190 patients
Phase 2Completed
NCT05683860WaVe Life SciencesWVE-004

Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)

Start: Dec 2022Est. completion: Jun 20238 patients
Phase 1/2Terminated
NCT04931862WaVe Life SciencesWVE-004

Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD)

Start: Jun 2021Est. completion: Jun 202335 patients
Phase 1/2Terminated
NCT03506425Ultragenyx PharmaceuticalTriheptanoin

A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)

Start: Jun 2018Est. completion: Mar 201915 patients
Phase 1/2Completed
NCT00036296TevaTalampanel

Effects of Talampanel on Patients With Advanced Parkinson's Disease

Start: Dec 2006Est. completion: Feb 200722 patients
Phase 1/2Completed
NCT06453668ITB MedTCD601

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

Start: Apr 2024Est. completion: Nov 202948 patients
Phase 1Recruiting
NCT04948645CalicoFosigotifator

A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Fosigotifator in Patients With Amyotrophic Lateral Sclerosis

Start: Sep 2021Est. completion: Jul 202531 patients
Phase 1Terminated
NCT04490096Biogen[11C]-PBR28

Multimodal Imaging Outcome Measures for ALS (Image ALS)

Start: Feb 2021Est. completion: Mar 20222 patients
Phase 1Terminated
NCT00964730TevaTalampanel

A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm

Start: Oct 2009Est. completion: Feb 2010135 patients
Phase 1Completed
NCT06743776MediciNovaMN-166

Scalable Expanded Access With Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

N/AAvailable
NCT06408727CleneCNM-Au8

Intermediate Expanded Access Protocol CNMAu8.EAP04

N/ATemporarily Not Available
NCT05271435BiosensicsPAMSys Activity Monitoring System

Digital Tools for Assessment of Motor Functions and Falls in ALS

Start: Oct 2021Est. completion: Jun 202620 patients
N/AActive Not Recruiting
NCT02795897BiogenGenomic Translation for Amyotrophic Lateral Sclerosis Care

Genomic Translation for Amyotrophic Lateral Sclerosis Care

Start: Jun 2016Est. completion: Jun 2022254 patients
N/ACompleted
NCT05966038Providence TherapeuticsALS/MND Natural History Study Data Repository

ALS/MND Natural History Study Data Repository

Start: Apr 2015Est. completion: Dec 20305,000 patients
N/ARecruiting

Related Jobs

Medical Science Liaison – Neurodegeneration (United States)

Prilenia TherapeuticsPrilenia Therapeutics
Remote
1w ago
$91K - $197K/yr

Sr. Manager, Analytics, Insights, and Market Research- Alzheimer's

BiogenBiogen
Cambridge, MA (Hybrid)
3w ago
$142K - $190K/yr

Neurology Key Account Manager – Fixed-Term (33 Months)

BiogenBiogen
Warsaw, Poland (Field Based)
3w ago

Principal Scientist, Computational Chemistry

BiogenBiogen
Cambridge, MA (Hybrid)
1mo ago
$141K - $188K/yr

People Operations Specialist (Part Time/Temporary)

AlectorAlector
South San Francisco, CA
1mo ago
$40 - $50/yr

Grant Writer (PhD)

SynaptrixSynaptrix
New York City
1mo ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
2 actively recruiting trials targeting 7,126 patients
15 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.